← Back to patent-cliff list
AZD-6234
Tier C — Watch / tradeAZD-6234
AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Amylin Receptor
Indications (approved)：Overweight, Obesity, Type 2 diabetes, 体重, Hepatic function decline, Renal impairment
Regional status
US
Phase III
2026-08-19
EU
Phase III
2026-08-19
China
Phase III
2026-08-19
Japan
Phase III
2026-08-19
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AZD-6234?
Approved indications include: Overweight, Obesity, Type 2 diabetes, 体重, Hepatic function decline, Renal impairment.
When does the AZD-6234 patent expire?
No public expiry year is available for AZD-6234 yet; this page updates once verified.
How do I get a quote for AZD-6234 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29